CardioSignal is a health technology company developing groundbreaking solutions for early detection of heart diseases. We are based in Turku, Finland and Palo Alto, CA, United States. The CardioSignal mobile application is a CE-marked class IIa medical device for the detection of atrial fibrillation, available in over 10 countries. The technology we are developing enables a digital cardiac biomarker for other major heart diseases as well.

CardioSignal is a brand and a product by Precordior. Originally an academic spinoff, the company’s patented motion sensor technology is built on a decade of research and algorithm development. 

Our purpose
We are supporting healthcare in battling the #1 killer of people in the world. With heart disease numbers only rising, we are facing a health and economic problem described as an epidemic by researchers and physicians around the world. 

Early identification and treatment of heart disease, such as atrial fibrillation, would help prevent strokes and heart attacks and improve outcomes for individuals and society.

CardioSignal by Precordior

Our team is growing and on the lookout for a Quality Specialist! If you are searching for meaningful work in the world of #healthtechnology, this position might be for you! 

https://lnkd.in/dhJbZ_i7

#healthtech #hearthealth #medicaldevices #qualitymanagement #wearehiring #openpositions

In our latest blog, we summarize the impact of atrial fibrillation in Europe and address the growing prevalence. Did you know that atrial fibrillation is very common, and that many experience it mild or no symptoms at all? The good news though: It can be treated. Early detection is key.

#hearthealth #digitalhealth #heartdisease #atrialfibrillation #cardiology #earlydetection #heartawareness #hearthealthy #healthtech
https://lnkd.in/d6jdGmM8

New #atrialfibrillation guidelines from the American College of Cardiology/American Heart Association Joint Committee are out!  

Selected picks from the perspective of atrial fibrillation prevention and advancing earlier detection among risk populations. 

The guideline:

✔ Emphasizes risk factor management throughout atrial fibrillation disease progression. 
✔ Introduces new disease stages that emphasizes atrial fibrillation as a progressive disease. Disease stages begin from being at-risk of atrial fibrillation. 
✔ Highlights the importance of utilizing a variety of strategies at different stages, ranging from prevention, lifestyle and risk factor modification, screening, and therapy.
✔ Recognizes that future research is needed on how prevention and modification of risk factors can be incorporated into daily clinical practice.
 
Our key takeaways:
 
↗  A clearer focus on prevention in atrial fibrillation is welcome due to the growing burden of atrial fibrillation and the growth of underlying risk factors (hypertension, diabetes etc.) 
↗ The delayed diagnostics and the often asymptomatic nature of the disease makes prevention critical to reduce atrial fibrillation onset, progression, and adverse outcomes (such as ischemic strokes).
↗  The field needs to be more proactive in providing evidence that patients at highest risk of developing atrial fibrillation would benefit from screening and preventive action. 
↗  Health inequity needs more focus in atrial fibrillation research.
 
ℹ American College of Cardiology(ACC) and American Heart Association (AHA) translate scientific evidence into clinical practice guidelines with recommendations to improve cardiovascular health. These guidelines provide a foundation for the delivery of quality cardiovascular care and are applicable to patients with or at risk of developing cardiovascular disease.

Read more://https://lnkd.in/gjuQVVpy
Image: AF Stages: Evolution of Atrial Arrhythmia Progression

#hearthealth #cardiology #healthcare #cardiovascularhealth #heartdisease #heartawareness #guidelines #digitalhealth #remotecare #healthtechnology #healthtech #mhealth #screening

We are excited to attend GIANT Health Event in London next week, an event that gathers everyone who's business is #health, tech, and innovation in the UK 🚀 Stop by to meet our team and to discuss how #digitalhealth can be harnessed for improved cardiac care - even at a distance. #hearthealth #healthtech #cardiology #healthtechnology #telemedicine #remotecare

In our latest blog post, we ask if health benefits serve those who are already healthy. Can more be done to engage those for preventive health who are at highest risk? 

Many times, the 5K runners, yogis and people already attending fitness classes are most engaged with wellness benefits. Do you have tips to share what employers can do to improve targeting preventive health efforts? Read our blog and share your thoughts 👇 

https://lnkd.in/gvRSwgw9

In our series of short blogs, we cover topical themes in the #healthtech space. Have a topic in mind? Let us know in the comments!

#employerhealth #wellness #benefitsmanagement #healthbenefits #digitalhealth #healthapp #mhealth #atrialfibrillation #hearthealth #heartdisease #healthpromotion #healthtech #healthcareinnovation #chroniccaremanagement #chroniccare

In a series of short blogs, we cover topical themes in the #healthtech space. Our latest snapshot addresses whether health tech is able to match the expectations of older adults. 

Age should not limit the use of digital health. Do you agree? Read more 👉  https://lnkd.in/dvPBCDWb

#heartdiseases #agetech #healthequity #digitalhealth #mhealth #hearthealth #healthapp

Happening tonight in Alexandria Center for Life Science in New York City! We are honored to be a nominee in #PrixGalien Awards in the Best Startup category. It’s a privilege to present our digital biomarker technology that has the power to boost scalability and accessibility in remote patient monitoring and remote care of cardiac conditions.
 
The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, acknowledges amazing companies for their dedication in delivering answers and improving health of patients around the world.
 
We are proud to be part of this list of innovators! Read more: https://lnkd.in/eu9CiH54
 
#digitalhealth #hearthealth #healthcare #healthtechnology #remotepatientmonitoring #cardiology #mhealth #telemedicine #gyrocardiography #heartdisease #healthcareinnovation

CardioSignal and Mehiläinen continue #populationhealth program for earlier detection of #atrialfibrillation. Read our latest news on how we overcame barriers in scalability and accessibility in order to provide digital tools for screening atrial fibrillation at home.

"At Mehiläinen, we are committed to focusing on the accessibility and ease of use of digital health services among our customers. This program removes many traditional challenges related to digital literacy and juggling additional devices. I am excited to be part of creating impactful care strategies that concretely improve health outcomes for our customers”, said Essi Kainonen, Medical Director, Digital Health Services at Mehiläinen. 

“Chronic conditions such as heart disease put a major strain on population health. Too often patients have already suffered a life-altering complication by the time they are diagnosed," said CEO, cardiologist Juuso Blomster.

#digitalhealth #healthtech #healthtechnology #cardiology #heartdisease #mhealth #hearthealth #telemedicine

#HLTH2023 is where the future of health happens ♥️ This event takes place in Las Vegas, October 8-11. We are here at booth 5929 to share insights on how smartphones can be harnessed to improve remote cardiac care. 

—> How to build population health programs to address the growing burden of #atrialfibrillation

—> How earlier detection of #heartdisease can be advanced in primary care 

—> Ways to scale rapid cardiac screening of patients with elevated cardiovascular risk in #telemedicine and #remotepatientmonitoring 

Intrigued to hear more? Connect with the CardioSignal team Lasse Leppäkorpi, Tero-Pekka Alastalo and Juuso Blomster today at booth 5929. 

#digitalhealth #hearthealth #healthtech #healthapp #gyrocardiography #cardiology #digitalhealthcare

We are excited to share our latest achievement in strengthening #AgeTech expertise! To break barriers in the scalability and accessibility of remote cardiac care technology among older adults, CardioSignal has become a portfolio company of AgeTech Collaborative™ from AARP® after completing its prestigious accelerator program. Joining the network will help gain key market insights and build growth in the rapidly growing AgeTech market. 

“Smartphones are everywhere. The future of care delivery means reorienting healthcare where the users are. For care delivery, the smartphone ecosystem offers unparalleled opportunities for engagement, efficiency, and better access to care,” said Tero-Pekka Alastalo (MD, PhD). 

✖ According to AARP, as much as 68% of people 50-plus do not think technology is designed with their age group in mind. 

☑ In our annual user surveys, 93% of people above 60 have found the CardioSignal technology to be very easy to use.

✔ Smartphone ownership has exploded in the 65+ age group over the past decade and now stands at 61%.

#remotecare #healthtech #healthapp #healthtechnology #cardiology #telemedicine #healthcare #hearthealth #heartdisease #gyrocardiography

CardioSignal develops groundbreaking solutions for the detection of heart diseases. It is a mobile application and a certified medical device for the detection of atrial fibrillation. The company's patented technology is built on a decade of research and algorithm development. CardioSignal is a brand and a product by Precordior.

COM:CARDIOSIGNAL

CardioSignal

Filings Not Available